ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $208,565 | -22.6% | 7,762 | +2.8% | 0.00% | -100.0% |
| Q2 2023 | $269,304 | +22.8% | 7,552 | -12.6% | 0.00% | 0.0% |
| Q1 2023 | $219,380 | -34.0% | 8,637 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $332,611 | +42.8% | 8,637 | +22.5% | 0.00% | 0.0% |
| Q3 2022 | $233,000 | -6.8% | 7,053 | -0.5% | 0.00% | 0.0% |
| Q2 2022 | $250,000 | +25.6% | 7,088 | +64.1% | 0.00% | 0.0% |
| Q1 2022 | $199,000 | -29.9% | 4,319 | +6.2% | 0.00% | 0.0% |
| Q4 2021 | $284,000 | +5.2% | 4,065 | -6.1% | 0.00% | 0.0% |
| Q3 2021 | $270,000 | -24.6% | 4,328 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $358,000 | +0.3% | 4,328 | -19.7% | 0.00% | 0.0% |
| Q1 2021 | $357,000 | +31.7% | 5,388 | +52.5% | 0.00% | 0.0% |
| Q4 2020 | $271,000 | +19.4% | 3,532 | -33.1% | 0.00% | 0.0% |
| Q3 2020 | $227,000 | +0.9% | 5,283 | +1.5% | 0.00% | -33.3% |
| Q2 2020 | $225,000 | – | 5,207 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |